--- title: "Legend Biotech (LEGN) news: offering" url: "https://aibio.space/companies/legend-biotech/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LEGN offering news. Legend Biotech news for investors: Legend Biotech develops CAR-T cell therapies for cancer and sells Carvykti, a multiple myeloma…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Legend Biotech is profitable on one drug and betting on in vivo CAR-T Legend Biotech has turned Carvykti into a profit and has cash for its pipeline. It depends on one product whose growth is slowing, has a new CEO and has an early pipeline led by a program with six patients at the active dose. Read the full desk view aibio.space Investor Rank · Opinion **7** /10 Positive view Carvykti has made Legend profitable with solid cash, but growth is slowing, competition is arriving, a new CEO is in place and the pipeline is early. - **Technology**: 2/2 - **Odds**: 1/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 1/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Commercial in myeloma.** Carvykti works and sold about $657 million in Q2, while in vivo CAR-T is early with 12 treated patients. - **Odds**: **Strong for label growth, long for the pipeline.** Filed applications get approved 90.6% of the time, but only 7.9% of drugs reach approval from phase I across all programs. - **Balance sheet**: **Solid for now.** About $965 million in cash and time deposits at June 30, with runway beyond 2026 per the company. - **Main risk**: **Concentration on one drug.** Carvykti growth is slowing and competition is arriving, under a new CEO. - **Watch next**: **Third-quarter results and the start of the U.S.** LB2501 study. ## Top news on Legend 1. 2026-06-23 Company Updates [Calidi Biotherapeutics appoints Corsee Sanders to board](https://aibio.space/news/calidi-biotherapeutics-appoints-corsee-sanders-board/) Dr. Corsee Sanders, a former Genentech/Roche and Celgene executive, joined the board as an independent director effective June 17, 2026. 2. 2026-06-17 Financings [Legend Biotech launches $225,000,000 ADS offering, then prices 7,700,000 ADSs at $29.35](https://aibio.space/news/legend-biotech-launches-225-000-000-ads-offering-then-prices-7-700-000/) The offering totals $225,995,000 before underwriting discounts. Underwriters hold a 30-day option for 1,155,000 more ADSs, and closing was expected on June 23, 2026. The shares priced below the last sale price of $33.52. ## Dates **No date given** Third-quarter 2026 financial results, including Legend's share of Carvykti collaboration revenue [Source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006593/f6k_101326.htm) **No date given** Start of the U.S. phase 1/2 study of LB2501 following the Oct. 15 IND clearance [Source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/exh_991.htm) **No date given** CARTITUDE-5 and CARTITUDE-6 front-line myeloma studies, listed in patient follow-up [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000014/q126pipeline.htm) ## The money Cash and cash equivalents and time deposits of about $965 million at June 30, 2026, including about $212 million net from a June offering. The company says this provides runway beyond 2026. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) Q2 2026 collaboration revenue of $326.1 million and license and other revenue of $61.4 million; Carvykti net trade sales were about $657 million (up 50%). Preliminary Q3 Carvykti net trade sales were about $710 million. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) ## Risks on the record - Revenue depends on Carvykti, which faces competition from Gilead's anito-cel and J&J bispecific combinations, according to Fierce Pharma; shares fell 10% on July 15 when second-quarter sales came out. [Source](https://www.fiercepharma.com/pharma/legend-biotech-ceo-abruptly-steps-down-without-permanent-replacement) - CEO transition: Ying Huang resigned effective July 24, 2026 and Ingrid Zhang became CEO on Sept. 15. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006050/exh_991.htm) - Tax uncertainty: income tax expense rose to $22.3 million in Q2 and an advance pricing agreement with Chinese tax authorities has not been executed. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) ## Questions investors ask ### What is aibio.space's Investor Rank for Legend Biotech? 7 out of 10, our positive view. Carvykti has made Legend profitable with solid cash, but growth is slowing, competition is arriving, a new CEO is in place and the pipeline is early. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### How much did Carvykti sell in the third quarter of 2026? Legend Biotech said Carvykti generated about $710 million in net trade sales in the quarter ended Sept. 30, 2026, up from about $657 million in the second quarter. The figure comes from Janssen and has not been verified by Legend. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006593/f6k_101326.htm) ### Who is the CEO of Legend Biotech? Ingrid Zhang became CEO on Sept. 15, 2026. She was previously chief commercial officer for Novartis International and succeeded interim CEO Alan Bash, after Ying Huang resigned in July. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006050/exh_991.htm) ### Is Legend Biotech profitable? Legend reported net income of $33.2 million for the second quarter of 2026, against a net loss of $125.4 million a year earlier. Adjusted net income was $63.1 million. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) ### What is LB2501? LB2501 is an off-the-shelf in vivo CD19/CD20 CAR-T therapy that creates CAR-T cells inside the patient. The FDA cleared its IND on Oct. 15, 2026 for a planned U.S. phase 1/2 study in B-cell lymphoma. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/exh_991.htm) ### How much cash does Legend Biotech have? Legend had about $965 million in cash and cash equivalents and time deposits at June 30, 2026. It says that provides financial runway beyond 2026. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) ### What is the latest Legend Biotech (LEGN) stock news? Our latest story on Legend Biotech, dated Jun 17, 2026: "Legend Biotech launches $225,000,000 ADS offering, then prices 7,700,000 ADSs at $29.35". The offering totals $225,995,000 before underwriting discounts. Underwriters hold a 30-day option for 1,155,000 more ADSs, and closing was expected on June 23, 2026. The shares priced below the last sale price of $33.52. [Source](https://aibio.space/news/legend-biotech-launches-225-000-000-ads-offering-then-prices-7-700-000/) ### What is Legend Biotech's latest stock offering or financing news? Our latest financing story, dated Jun 17, 2026: "Legend Biotech launches $225,000,000 ADS offering, then prices 7,700,000 ADSs at $29.35". The offering totals $225,995,000 before underwriting discounts. Underwriters hold a 30-day option for 1,155,000 more ADSs, and closing was expected on June 23, 2026. The shares priced below the last sale price of $33.52. [Source](https://aibio.space/news/legend-biotech-launches-225-000-000-ads-offering-then-prices-7-700-000/) ### Who were the underwriters or placement agents on Legend Biotech's offering? From our story: Morgan Stanley, Jefferies, Citigroup and Deutsche Bank Securities are joint bookrunners, and Morgan Stanley Asia Limited, Jefferies LLC and Citigroup Global Markets Inc. act as representatives of the underwriters. [Source](https://aibio.space/news/legend-biotech-launches-225-000-000-ads-offering-then-prices-7-700-000/) ### Is Legend Biotech a smaller reporting company? SEC records list Legend Biotech Corporation's filer category as: Large accelerated filer. Source ### Where is Legend Biotech headquartered? SEC records list its business address as 2101 COTTONTAIL LANE, SOMERSET, NJ, 08873. Source ### When does Legend Biotech's fiscal year end? Legend Biotech Corporation's fiscal year ends on December 31, per SEC records. Source ### What did Legend Biotech last file with the SEC? Its most recent filing in our record is a 6-K filed 2026-10-15. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/f6k_101426.htm) ### What industry is Legend Biotech in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ### Which other companies' news mentions Legend Biotech? Legend Biotech is named in 1 of our story about other companies, most recently: "Calidi Biotherapeutics appoints Corsee Sanders to board" (Jun 23, 2026). [Source](https://aibio.space/news/calidi-biotherapeutics-appoints-corsee-sanders-board/) ## Legal and investor matters Checked against Legend Biotech filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. The Legal and Administrative Proceedings section of the 20-F filed 2026-03-10 (Item 8.A) describes one matter, the 2seventy bio patent complaint in the Unified Patent Court. It does not mention a securities class action or derivative suit. This covers that filing only. [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm) 1. 2026-07-22 Governance Legend Biotech CEO Ying Huang resigns; Alan Bash named interim, Ingrid Zhang appointed Legend said in a 6-K that on July 22, 2026 Ying Huang notified the board of his resignation as chief executive officer and director, effective July 24, 2026. The filing states the resignation was not the result of any disagreement with the company. The board appointed Alan Bash, President of CARVYKTI, as interim chief executive officer. A later 6-K says Ingrid Zhang was appointed chief executive officer effective September 15, 2026. [Legend Biotech 6-K filed 2026-07-27](https://www.sec.gov/Archives/edgar/data/1801198/000119312526316760/d56062d6k.htm) 2. 2026-06-17 Financing Legend Biotech prices 7.7 million ADS offering at $29.35, expected net proceeds about $211.6 million Legend disclosed in a 6-K that on June 17, 2026 it entered into an underwriting agreement with Morgan Stanley Asia Limited, Jefferies LLC and Citigroup Global Markets Inc. for an offering of 7,700,000 American Depositary Shares, representing 15,400,000 ordinary shares, at $29.35 per ADS. Expected net proceeds were about $211.6 million. Underwriters held a 30-day option for up to 1,155,000 more ADSs, and closing was expected on or about June 23, 2026. [Legend Biotech 6-K filed 2026-06-22](https://www.sec.gov/Archives/edgar/data/1801198/000119312526277556/d81029d6k.htm) 3. 2026-01-05 Litigation 2seventy bio files Unified Patent Court suit against Legend and Janssen Legend's 20-F says that on January 5, 2026 2seventy bio, Inc., a subsidiary of Bristol-Myers Squibb, filed a patent infringement complaint in the Unified Patent Court against Legend and its collaborator Janssen. The complaint asserts that 2seventy is exclusive licensee of European Patent No. 3 689 383, owned by the National Institutes of Health, and alleges that Carvykti manufacturing and sales in Europe infringe it. It seeks unspecified damages. Unified Patent Court · Status: filed [Legend Biotech 20-F filed 2026-03-10](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Carvykti (cilta-cel, BCMA CAR-T) | Relapsed/refractory multiple myeloma | Approved; about $710 million preliminary Q3 2026 net trade sales [Source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006593/f6k_101326.htm) | | Carvykti, CARTITUDE-5 and -6 | Newly diagnosed multiple myeloma (front-line) | Patient follow-up (company pipeline chart); CARTITUDE-10 enrolling [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000014/q126pipeline.htm) | | LB2501 (in vivo CD19/CD20 CAR-T) | Relapsed/refractory B-cell non-Hodgkin lymphoma | Phase 1 in China; FDA IND cleared Oct. 15, 2026 for U.S. phase 1/2 [Source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/exh_991.htm) | | LB2102 (DLL3 CAR-T, licensed to Novartis) | Small-cell lung cancer and large-cell neuroendocrine carcinoma | Phase 1; ORR 28.6% at higher doses [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) | | LB1908 (Claudin 18.2 CAR-T) | Gastric and pancreatic cancers | Phase 1, met primary endpoint (company pipeline chart) [Source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000014/q126pipeline.htm) | Opinion · Devil's advocate ## Fact-check-o-meter Some gaps Legend's commercial numbers hold up; the early-data language runs ahead of 20 patients and six Legend's sales, cash and runway statements match its filings, and the 20-F discloses a patent complaint rather than any securities litigation. The softer spots are scientific framing: a "curative potential" statement rests on a 20-patient single-arm cohort, and a platform "validation" claim rests on six patients in an investigator-run phase 1 study. The profit goal is defined on an adjusted basis. 1. Science · weight medium "Curative potential" quote rests on a 20-patient single-arm cohort **The company said:** "These five-year data, showing that 50% of patients remained alive and progression-free after a single CARVYKTI infusion, reinforce the growing body of evidence supporting the unique curative potential of CARVYKTI" [source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006229/exh_991.htm) **The record says:** The release itself says the data come from "CARTITUDE-2 Cohort A (n=20)" and that "10 of 20 patients (50%) remained alive and progression-free". ClinicalTrials.gov lists CARTITUDE-2 as a phase 2, single-group, unmasked study with minimal residual disease negativity as the primary outcome. The release also notes that since the earlier analysis "one patient developed a new hematologic malignancy (acute myeloid leukemia) and two deaths occurred due to progressive disease and new cancer." [source](https://clinicaltrials.gov/study/NCT04133636) **Our view:** The result is encouraging and the safety follow-up is disclosed. A single-arm cohort of 20 with no control cannot support a word like curative on its own, and the confidence around 50% is wide. 2. Science · weight medium "Validating" an in vivo CAR-T platform on six patients **The company said:** "we achieved a significant innovation milestone with the first-in-human clinical readout for LB2501, validating our in vivo CAR-T platform." [source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) **The record says:** The same release reports "a 100% ORR (6/6) and 83.3% CR (5/6) at the higher dose level (DL2)", with responses ongoing at data cutoff. ClinicalTrials.gov lists the China study (NCT07002112) as a phase 1, single-group, open-label trial with an estimated 30 participants, sponsored by The First Affiliated Hospital with Nanjing Medical University, and its primary outcomes are safety, pharmacokinetics and the recommended phase 2 dose. The Oct. 15 release says the FDA cleared the IND for a U.S. phase 1/2 study. [source](https://clinicaltrials.gov/study/NCT07002112) **Our view:** Six responders at a higher dose is an early signal, not validation of a platform. Durability, safety in larger groups and the U.S. study will do the validating. 3. Press release vs filing · weight low Runway and profit claims use an adjusted definition **The company said:** "Cash and cash equivalents, and time deposits of approximately $965 million as of June 30, 2026, which Legend Biotech believes will provide financial runway beyond 2026, when Legend Biotech believes it will achieve a company-wide profit" [source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) **The record says:** A footnote in the release says "Company-wide profit defined as Adjusted Net Income". For the quarter, net income was $33.2 million and adjusted net income was $63.1 million. The release adds that "a formal agreement has not yet been executed" on the Chinese advance pricing agreement and that "the final outcome with a tax authority may result in a tax liability that is materially different from that reflected in the consolidated financial statements." The 20-F says management expects cash to fund operations "for at least the next 12 months". [source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) **Our view:** The runway statement matches the 20-F. Readers should know the profit target is adjusted, and the open tax matter could move reported results either way. 4. Press release vs filing · weight low Headline sales are J&J-reported, and Legend's share is about half **The company said:** "CARVYKTI (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million" [source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) **The record says:** The release reports Legend's collaboration revenue at $326.1 million for the quarter. For the preliminary third-quarter figure of about $710 million, the 6-K says it is "based on information provided to Legend Biotech by Janssen, and Legend Biotech has not independently verified the accuracy of such sales figure" and has not been audited or reviewed. [source](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006593/f6k_101326.htm) **Our view:** This is standard collaboration reporting and the caveat is clear in the filing. The headline number is the partner's sales, so Legend's own revenue is the figure to track. 5. Legal and disclosure record · weight medium Patent complaint in the Unified Patent Court; no securities litigation disclosed **The record says:** Under Legal and Administrative Proceedings, the 20-F says: "On January 5, 2026, plaintiff 2seventy bio, Inc., a wholly-owned subsidiary of Bristol-Myers Squibb Company, filed a patent infringement complaint in the Unified Patent Court against us and our collaborator including Janssen." The complaint concerns European Patent No. 3 689 383 and "seeks unspecified monetary damages"; the company says it intends to defend vigorously. No securities litigation or enforcement is disclosed in that section. [source](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm) **Our view:** The complaint targets European sales of the only marketed product. The 20-F gives no timetable or damages estimate, so any ruling or settlement would be new information. Documents we compared - [Press release: Q2 2026 results (6-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/a991earningsreleaseq22026.htm) 2026-08-11 - [Form 6-K: preliminary Q3 2026 Carvykti sales](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006593/f6k_101326.htm) 2026-10-13 - [Press release: CARTITUDE-2 five-year data (6-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006229/exh_991.htm) 2026-09-25 - [Press release: LB2501 IND clearance (6-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/exh_991.htm) 2026-10-15 - [Form 20-F for year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm) 2026-03-10 - [ClinicalTrials.gov NCT04133636 (CARTITUDE-2)](https://clinicaltrials.gov/study/NCT04133636) 2026-09-25 - [ClinicalTrials.gov NCT07002112 (LB2501 China study)](https://clinicaltrials.gov/study/NCT07002112) 2026-05-14 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LEGN on TradingView](https://www.tradingview.com/symbols/NASDAQ-LEGN/). ## SEC filings and registration - **SEC name**: Legend Biotech Corp - **CIK**: 1801198 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LEGN (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 2101 COTTONTAIL LANE, SOMERSET, NJ, 08873 - **Phone**: 732-850-5598 - **Shares outstanding**: 369,886,369 as of 2025-12-31 (20-F filed 2026-03-10) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/f6k_101426.htm) filed 2026-10-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006593/f6k_101326.htm) filed 2026-10-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006229/f6k_092426.htm) filed 2026-09-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006215/f6k_092326.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006050/f6k_091526.htm) filed 2026-09-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006027/f6k_091426.htm) filed 2026-09-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1801198/000117184326005623/f6k_081826.htm) filed 2026-08-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000022/legn-20260630.htm) filed 2026-08-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001801198), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/legend-biotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Legend Biotech (LEGN) news: offering", 2026-10-31, https://aibio.space/companies/legend-biotech/